Forte Biosciences Stock Forecast, Price & News

-0.02 (-0.07 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume204,297 shs
Average Volume215,993 shs
Market Capitalization$404.76 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Forte Biosciences logo

About Forte Biosciences

Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.04 out of 5 stars

Medical Sector

222nd out of 2,222 stocks

Pharmaceutical Preparations Industry

115th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Forte Biosciences (NASDAQ:FBRX) Frequently Asked Questions

Is Forte Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Forte Biosciences stock.
View analyst ratings for Forte Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Forte Biosciences?

Wall Street analysts have given Forte Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Forte Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Forte Biosciences?

Forte Biosciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,270,000 shares, an increase of 38.5% from the June 15th total of 916,800 shares. Based on an average daily volume of 169,800 shares, the short-interest ratio is currently 7.5 days. Currently, 13.0% of the company's stock are short sold.
View Forte Biosciences' Short Interest

When is Forte Biosciences' next earnings date?

Forte Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Forte Biosciences

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) issued its quarterly earnings data on Sunday, May, 9th. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.03.
View Forte Biosciences' earnings history

What price target have analysts set for FBRX?

6 Wall Street analysts have issued 1-year price targets for Forte Biosciences' shares. Their forecasts range from $70.00 to $105.00. On average, they anticipate Forte Biosciences' share price to reach $81.60 in the next year. This suggests a possible upside of 172.4% from the stock's current price.
View analysts' price targets for Forte Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Forte Biosciences' key executives?

Forte Biosciences' management team includes the following people:
  • Dr. Paul A. Wagner, Pres, CEO & Chairman (Age 51, Pay $776.92k)
  • Mr. Antony A. Riley CPA, Chief Financial Officer (Age 54, Pay $450.66k)
  • Dr. Daniel J. Burge, Chief Medical Officer (Age 59)
  • Dr. Henry W. Talbot Jr., Ph.D., Head of Upstream Manufacturing & Quality (Age 69)

Who are some of Forte Biosciences' key competitors?

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), electroCore (ECOR), (GAU), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN).

What is Forte Biosciences' stock symbol?

Forte Biosciences trades on the NASDAQ under the ticker symbol "FBRX."

Who are Forte Biosciences' major shareholders?

Forte Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Lindbrook Capital LLC (0.01%).

Which institutional investors are buying Forte Biosciences stock?

FBRX stock was purchased by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC.

How do I buy shares of Forte Biosciences?

Shares of FBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Forte Biosciences' stock price today?

One share of FBRX stock can currently be purchased for approximately $29.96.

How much money does Forte Biosciences make?

Forte Biosciences has a market capitalization of $404.76 million and generates $40,000.00 in revenue each year. The company earns $-46,490,000.00 in net income (profit) each year or ($6.32) on an earnings per share basis.

How many employees does Forte Biosciences have?

Forte Biosciences employs 9 workers across the globe.

What is Forte Biosciences' official website?

The official website for Forte Biosciences is

Where are Forte Biosciences' headquarters?

Forte Biosciences is headquartered at 1124 W CARSON STREET MRL BUILDING 3-320, TORRANCE CA, 90502.

How can I contact Forte Biosciences?

Forte Biosciences' mailing address is 1124 W CARSON STREET MRL BUILDING 3-320, TORRANCE CA, 90502. The company can be reached via phone at 310-618-6994 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.